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Pharmacovigilance is vital for public health and patient safety and includes all 
activities relating to the detection, assessment and prevention of adverse effects due 
to medicinal products (see WHO 2004) . Despite risk assessment before marketing 
authorisation, all medicines might produce adverse drug reactions (ADRs) during 
therapeutic use after marketing (Belton and the European Pharmacovigilance 
Research Group 1997) .
Overall, the findings of our comparative assessment of six national pharma-
covigilance systems for biological medicinal products (biologicals) are rich and 
encouraging, yet somehow sobering . The in-depth analysis includes six important 
aims corresponding to the structure of the manuscript .
Chapter 2 illustrates that because all medicines might produce ADRs, timely 
and accurate reporting is important to ensure post-market authorisation safety . 
Due to their intrinsic characteristics, this is particularly true regarding biologicals .
Chapter 3 illustrates that the EU pharmaceuticals regulation was mainly con-
cerned with pre-market authorisation up until the 1990s, whereas pharmacovig-
ilance was rather neglected . Since that time, pharmacovigilance has begun to 
become an important aspect of EU regulation . The system of pharmacovigilance 
has been substantially reformed with the adoption of Directive 2010/84/EU, which 
amended Directive 2001/83/EC . Today, extended provisions for Member States to 
establish national pharmacovigilance systems are in place through Article 102 of 
Directive 2010/84/EU .
Chapter 4 stresses, however, that many countries have a serious transposition 
problem in their national pharmacovigilance systems . Almost 85 percent of the 
national transposition instruments are not transposed on time, and in fact are 
delayed up to more than two years .
Chapter 5 takes into account the various types of national public health systems 
and presents different perceived challenges and best practices for each Member 
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State; the variation in national public health corresponds with the variation in 
national pharmacovigilance systems .
Chapter 6 focuses on the core finding which is ADR underreporting . Based on 
our research methodology involving desk and field research, we have compared 
the major challenges and identified individual as well as organisational factors 
impeding appropriate ADR reporting .
Notwithstanding the recorded progress across Member States, the reform of the 
EU pharmacovigilance system could be further improved . Important challenges 
remain regarding both legal transposition and practical implementation across 
Europe . Drawing on these challenges, this chapter describes a list of recommen-
dations with a view to improving practical implementation in the Member States . 
In order to facilitate a better understanding among Member States, identified best 
practices based on the comparative analysis are included as well .
The first part describes specific recommendations structured along Article 102 
of Directive 2010/84/EU . The article specifies the general provisions on pharma-
covigilance and lays down a number of measures regarding ADR reporting . We 
concentrate on the role of healthcare providers because Article 102 further specifies 
that for the purposes of points (a) and (e) of the first paragraph the Member States 
may impose specific obligations on doctors, pharmacists and other healthcare 
professionals .
In the second part, more general recommendations are derived from the specific 
measures regarding ADR reporting . These general recommendations have to be 
understood in the context of different ideal systems of national healthcare .
7.1 Specific Recommendations in Relation to Article 102
7.1 Specific Recommendations in Relation to Article 102
In accordance with Article 102, the Member States shall:
a . take all appropriate measures to encourage patients, doctors, pharmacists and 
other healthcare professionals to report suspected adverse reactions to the 
national competent authority; for these tasks, organisations representing con-
sumers, patients and healthcare professionals may be involved as appropriate;
This provision is a cornerstone of the pharmacovigilance reform, because it in-
cludes for the first time patients as actors in national pharmacovigilance systems . 
However, the analysis revealed that patients lack awareness regarding their role in 
pharmacovigilance and therefore often do not report ADRs .
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•	 Recommendation 1: In order to tackle underreporting by patients, European, 
national and regional authorities should invest in awareness-raising campaigns 
to increase the public knowledge about pharmacovigilance and ADR reporting .
•	 Recommendation 2: Authorities should raise awareness in the short term 
through various means of communication, e .g . websites, social media, leaflets 
(best practice: Poland, the United Kingdom) as well as in the long term through 
cooperation with schools to educate future generations (best practice: Portugal) .
Although doctors, pharmacists and other healthcare providers are “classic” actors in 
pharmacovigilance, the analysis also revealed that the problem of underreporting 
is still prevalent . For a number of reasons, healthcare professionals often do not 
report ADRs .
•	 Recommendation 3: In order to tackle underreporting by healthcare providers, 
national authorities and healthcare institutions should invest in awareness-raising 
campaigns to increase professional knowledge about pharmacovigilance and 
sensitise relevant actors about its particular importance to ensure public health .
In the analysis, a distinction was made between quantity (number of ADR reports) 
and quality (value of information in ADR reports) . While awareness-raising cam-
paigns are expected to increase quantity, additional measures need to be implemented 
to increase the quality of ADR reporting as well .
•	 Recommendation 4: In order to improve both the quantity and quality of ADR 
reports, university classes about the importance of pharmacovigilance and the 
need for ADR reporting should be mandatory for every medical and pharmacy 
student (best practice: Finland) .
•	 Recommendation 5: In addition, European, national or regional authorities 
should organise advanced post-graduate training on a regular basis to ensure 
that healthcare professionals acquire the necessary skills for coping with the 
complex task of ADR reporting .8
•	 Recommendation 6: Healthcare professionals should also be trained to encour-
age patients to report and to assist them, if needed, with high-quality reporting .
8 Such training should include practical and legal counseling in order to alleviate the fear 
of litigation . However, this recommendation is contingent on the national legal system 
in which ADR reporting occurs (see below) .
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Because healthcare providers working in healthcare institutions are not isolated 
actors, institutional factors contribute to the effective implementation of phar-
macovigilance measures . The analysis revealed a number of challenges in this 
respect . For instance, ADR reporting is often perceived to be time-consuming and 
incompatible with other tasks .
•	 Recommendation 7: Healthcare institutions, in line with the general health 
policies of their Member State, should facilitate ADR reporting through stream-
lined internal processes .
•	 Recommendation 8: All stakeholders at the national level should improve 
mechanisms of cooperation . This not only includes competent authorities, but 
also industry and patients’ associations as well as research and training facilities 
such as universities .
b . facilitate patient reporting through the provision of alternative reporting formats 
in addition to web-based formats;
Because the reform of the pharmacovigilance system includes patients for the first 
time, a related stipulation was included to facilitate patient reporting through 
alternative formats . Despite these formats, the analysis revealed that formatting 
adds to the challenges regarding patients’ reporting .
•	 Recommendation 9: In order to facilitate ADR reporting for patients, Member 
States should offer a wide range of possible communication channels, including 
web-based and paper-based formats .
•	 Recommendation 10: Both web-based and paper-based formats should be 
designed to be as user-friendly as possible . For web-based formats, IT solu-
tions should be developed to guide patients through the format and to ensure 
the completeness of reports . All formats should be accompanied by accessible 
manuals written in layman’s terms .
SCOPE data indicates that user-friendly formatting helps increase ADR reporting 
by patients (Jan, Radecka 2015: 63-64) . Hence, in order to follow up on these rec-
ommendations, Member States should engage in mutual learning and sharing of 
best practices within the framework of SCOPE or otherwise .
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c . take all appropriate measures to obtain accurate and verifiable data for the 
scientific evaluation of suspected adverse reaction reports;
This provision is relevant insofar as it indicates the importance of scientific eval-
uation of individual reports regarding assessing the causality of a drug and the 
related ADR(s) . The analysis revealed that often information is not available due 
to technical reasons, for instance when databases are not compatible .
•	 Recommendation 11: In order to cope with information overload and to facil-
itate the process of submitting ADR reports, national and regional competent 
authorities should improve interconnectivity of IT systems, such as for instance 
those of general practitioners, hospitals, pharmacies and the national competent 
authority’s ADR reporting system (best practice: United Kingdom) .
•	 Recommendation 12: In addition to measures for facilitating patient reporting, 
national and regional competent authorities should also establish mechanisms 
to provide mandatory feedback to reporting patients .
d . ensure that the public is given important information on pharmacovigilance 
concerns relating to the use of a medicinal product in a timely manner through 
publication on the web-portal and through other means of publicly available 
information as necessary;
As mentioned in Chapter 3, this stipulation was included through an amendment of 
the European Parliament (EP) during the legislative process leading to the adoption 
of Directive 2010/84/EU . Drawing on the precautionary principle, the inclusion is 
geared towards dissemination of information to healthcare professionals and patients .
Drawing on the comparative analysis and the various recommendations dealing 
with other stipulations of Article 102, we can provide a general recommendation 
in this respect .
•	 Recommendation 13: With a view to effective communication of pharma-
covigilance information to patients, stakeholders at the national and European 
level should build on existing mechanisms of cooperation and should strive to 
build additional mechanisms in line with the means applied for raising general 
awareness of pharmacovigilance (best practice: Germany) .
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e . ensure, through the methods for collecting information and where necessary 
through the follow-up of suspected adverse reaction reports, that all appropriate 
measures are taken to identify clearly any biological medicinal product pre-
scribed, dispensed or sold in their territory which is the subject of a suspected 
adverse reaction report, with due regard to the name of the medicinal product, 
in accordance with Article 1(20), and the batch number;
This provision is of particular relevance regarding the traceability of biologicals . 
The analysis revealed that the practices of ADR reporting in the Member States 
do not ensure traceability throughout . Across Member States, batch numbers are 
not recorded by healthcare professionals as a routine task . Because biologicals are 
a special case of general ADR reporting, similar recommendations can be derived .
•	 Recommendation 14: In order to tackle underreporting of batch numbers and 
thereby facilitate the correct and timely traceability of biologicals, healthcare 
professionals should receive additional training to both increase awareness about 
the particular relevance of ADR reporting related to biologicals and to acquire 
the necessary skills to do so (best practice: Finland) .
•	 Recommendation 15: Healthcare institutions, in line with the general health 
policies of their Member State, should facilitate ADR reporting through stream-
lined internal processes and improved mechanisms of cooperation .
7.2 General Recommendations: National Healthcare 
Systems and Policy Options for Pharmacovigilance
7.2 General Recommendations
Drawing on the specific recommendations in relation to Article 102, we have devel-
oped general recommendations in the context of 1) the individual level of healthcare 
providers reporting ADRs; 2) the organisational level of healthcare institutions that 
provide for the environment in which healthcare professionals fulfil their tasks; 
and 3) the systemic level of pharmacovigilance in the Member States .
Individual Level of Healthcare Providers Reporting ADRs
Our analysis revealed that in some countries, medical liability presents an important 
impediment to ADR reporting by healthcare professionals . However, the fear of 
medical liability is contingent on the national health policy and the legal system 
on which it is based .
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In general, there are two systems of compensation for patients that have suffered 
from medical injuries (see Simon and Jansen 2009) . On the one hand, so-called 
no-fault systems provide compensation through national healthcare services . On 
the other hand, private healthcare providers or even individual healthcare pro-
fessionals can be held liable . Hence, no-fault systems are usually associated with 
healthcare systems in which states are the main providers of health services and 
claims made by patients are made directly with them (see Romeo-Casabona 2009) . 
In our sample, France, for instance, has a no-fault system, whereas Portugal and 
Germany have fault-based models (Essinger 2009) .9
In this respect, the Council of Europe put forward a number of recommenda-
tions to improve patient safety and prevent adverse events in healthcare (Council 
of Europe 2009) . Regarding ADR reporting, the recommendations are very similar 
to the provisions enshrined in Article 102 of Directive 2010/84/EU . However, the 
recommendations are based on a no-fault approach in which patients’ rights ought 
to be accommodated with the requirements of extensive ADR reporting . There-
fore, the recommendations include that legal protection of reporting healthcare 
professionals ought to be ensured .
During the reform of the EU pharmacovigilance system, the European Parlia-
ment aimed to include the same approach by amending Article 102, stating that 
“reporting of suspected adverse reactions due to medication errors should be on 
a ‘no blame’ basis, and should be legally privileged” (European Parliament 2010) .
Due to the diversity of national health systems, it is not surprising that this 
amendment was rejected by Member States . Its inclusion would imply a total over-
haul of established legal principles going beyond pharmacovigilance .
•	 Recommendation on the individual level of healthcare providers reporting 
ADRs: However, taking into account national diversity in health-related and 
legal terms, it is important to recognise that fault-based systems are an import-
ant impediment for ADR reporting . A general and cautious recommendation 
would then call on the Member States to enable healthcare professionals to 
report ADRs without fear of liability . This could be pursued not only by prac-
tical and legal counselling for healthcare professionals, but also by legal means 
through strengthening confidentiality or setting up compensation schemes for 
patients’ claims .
9 However, simple categorisations cannot be made because the issue of patients’ claims 
and compensations is a highly complex legal issue (see Romeo-Casabona 2009) .
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Organisational Level of Healthcare Institutions That Provide for the 
Environment in Which Healthcare Professionals Fulfil Their Tasks
Our analysis revealed that in many countries, the reporting of an ADR is perceived 
as admitting a failure . Therefore, healthcare professionals may decide not to report .
Regarding the implementation of Article 102, we have derived a specific rec-
ommendation calling for awareness-raising campaigns to increase professional 
knowledge about pharmacovigilance . While such campaigns are important for 
healthcare professionals in order to be aware of ADR reporting, this general rec-
ommendation points to a broader problem at the institutional level .
At this level, the behaviour of individuals is affected by institutional norms 
and values . That ADRs are seen as failures is one such value . Another one is the 
perceived loss of reputation . These norms and values cannot be changed by creat-
ing incentives at the individual level . Instead, national policy makers, healthcare 
providers and hospital management are called on to introduce a different culture 
of care and patient safety in which ADR reporting is seen as a key responsibility 
of healthcare professionals .
This general recommendation, however, has to be qualified by stressing that there 
are different corporate cultures in national institutions of healthcare provisions . The 
example of Finland is a case in point; hospitals in Finland are run based on strict 
hierarchical structures . On the one hand, change can be more easily implemented 
from top to bottom in this kind of organisation . If, on the other hand, top man-
agement is resistant to change, a hierarchical organisation increases the chance of 
resistance from healthcare professionals in their day-to-day work .
•	 Recommendation on the organisation level of healthcare institutions that 
provide for the environment in which healthcare professionals fulfil their 
tasks: By all means, pharmacovigilance should receive a more prominent role 
in the education of healthcare professionals, be they doctors, pharmacists or 
nursing staff . Cultural changes at the institutional level in hospitals and other 
healthcare providers can only be internalised by healthcare professionals if the 
underlying values and benefits of ADR reporting are included in the curricula of 
universities and other training facilities . Such long-term strategies are essential to 
affect the “corporate” culture in the healthcare institutions of the Member States .
Systemic Level of Pharmacovigilance in Member States
Several of our respondents considered a high level of collaboration between the 
relevant actors to be particularly beneficial for the process of ADR reporting . Thus, 
as a general recommendation, Member States can be called on to improve cooper-
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ation among all actors in the national pharmacovigilance systems . The underlying 
assumption here is that inclusive systems are an important precondition for the 
effective implementation of ADR reporting .
This recommendation, however, has to be qualified by stressing the diversity of 
national systems . Some Member States have centralised systems of pharmacovig-
ilance, and others have de-centralised systems . Some Member States have separate 
systems for biologicals, while others do not . Calls for further cooperation thus 
have to take into account the institutional structure of healthcare providers and 
the respective corporate cultures .
Whereas Portugal, for instance, has introduced regional centres after initially 
establishing a centralised system, this option might not be available for all Member 
States . Germany, for example, has a centralised system . Yet sectoral associations 
provide functional links between patients, healthcare providers and national 
competent authorities .
In general, subsidiarity is a key concept here . Challenges for national pharma-
covigilance systems, which should be addressed in the short term, e .g . training 
and awareness raising, should be devised in line with existing systemic features of 
national health systems . Long-term strategies require substantial reform of these 
systems and go beyond the implementation of the EU pharmacovigilance system .
A case in point is the particular challenge of the German pharmacovigilance 
system . Here, data protection is an important impediment . Some Member States 
have impeding policies in place which are entrenched in the national political 
culture and which cannot be changed easily . After all, such changes require trade-
offs of competing policy objectives at the EU level and, even more important, at 
the national level .
Another case in point of system-level impediment is the economic crisis . As 
could be seen in the various country chapters, the scarcity of resources more or less 
affects all Member States . However, the problem is particularly acute in Southern 
European Member States such as Portugal, where the national pharmacovigilance 
system is only slowly recovering from the deep financial and personnel cuts in the 
recent years . By all means, the scarcity of financial and human resources has to 
be seen as a structural factor regarding the regulation of complex policy issues, of 
which pharmaceuticals policy is just one .
•	 Recommendation on the systemic level of pharmacovigilance in the Member 
States: In general, national and regional competent authorities working under 
the auspices of national ministries should be endowed with sufficient financial 
means to fulfil their functions . Likewise, healthcare institutions should be en-
dowed with sufficient means . Sound finances enable healthcare institutions to 
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rely on a stronger workforce which reduces the workload of individual healthcare 
professionals and increases the possibility of extended ADR reporting .
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